Sanofi adlyxin no longer available in the us 2023?

See the DrugPatentWatch profile for adlyxin

What happened to Sanofi's Adlyxin in 2023?

Adlyxin, an injectable medication developed by Sanofi and AstraZeneca, was used to treat adults with type 2 diabetes and adults with type 2 diabetes with established cardiovascular disease [1]. However, according to a notice from the FDA, Adlyxin's availability has been affected by patent issues [2].

How long will Adlyxin be unavailable due to patent issues?

As per DrugPatentWatch.com, the patent for Adlyxin is set to expire in 2024, which may lead to the entry of generic versions of the drug in the US market [3]. Although this might indicate a partial return of Adlyxin's availability in the US for at least part of 2023, patients and prescribers remain concerned about the current availability of Adlyxin.

Will biosimilars affect Adlyxin's availability, or will Adlyxin's patent expiry be a turning point?

Adlyxin's patent expiry is likely to lead to cheaper biosimilar versions becoming available on the market. Sanofi has faced challenges from biosimilars in the past. It remains unclear which biosimilars will be approved or when they might become available in the US.

What does the Sanofi Adlyxin patent expiry mean for patients, and when can they expect alternatives?

Patients taking Adlyxin can continue their treatment until advised by their doctor to stop. The exact timeline for the availability of biosimilars or generic Adlyxin in the US remains unclear, and patients are encouraged to discuss their treatment options with their healthcare providers.

Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/lyxumia
[2] https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-final-public-notice-sanofi-aventis-u-s-inc-sanofi-lyxumia
[3] https://drugpatentwatch.com/patent/US10487617/